Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Conbercept + VEC for Retinoblastoma
NCT04990271Phase 2Unknown
- Sponsor
- Chengdu Kanghong Pharmaceutical Group Co., Ltd.
- Start
- Jul 2021
- Primary completion
- Apr 2023
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
A Phase 2 trial of conbercept in retinoblastoma (Rb), sponsored by Chengdu Kanghong Pharmaceutical Group Co., Ltd.. Status: unknown.
02
Drugs
conbercept
03
Conditions
retinoblastoma (Rb)
Beyond the preview
Go deeper on NCT04990271.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04990271.